Unknown

Dataset Information

0

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500?000 copies/mL: week 48 outcomes from ACTG 5353.


ABSTRACT: BACKGROUND:The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA 1000-500?000 copies/mL. Optimal ART for treatment-naive individuals must be durable. OBJECTIVES:The aim of this study was to estimate the efficacy and safety of dolutegravir plus lamivudine at week 48 and compare the efficacy in participants with baseline HIV-1 RNA ?100?000 copies/mL versus >100 000 copies/mL. METHODS:Virological success was defined as HIV-1 RNA <50 copies/mL by FDA Snapshot criteria. Definition of virological failure included confirmed HIV-1 RNA >200 copies/mL at week 24 or later. The proportion of participants with virological success was estimated using two-sided exact Clopper-Pearson 95% CI. Comparison between screening HIV-1 RNA (?100?000 versus >100?000 copies/mL) strata was carried out by Fisher's exact test. The study was registered with ClinicalTrials.gov, number NCT02582684. RESULTS:A total of 120 enrolled eligible participants were included in the analysis. At week 48, 102 of the 120 participants (85%; 95% CI 77%-91%) had virological success. Virological success was similar between screening HIV-1 RNA groups. Six (5%) participants had virological non-success and one additional participant experienced virological failure while on study but off study treatment. No new drug resistance mutations were observed. Six (5%) participants had study-related grade 3 or higher adverse events and none discontinued study treatment. CONCLUSIONS:These results add to the evidence that dolutegravir plus lamivudine is a safe and effective option for initial ART in individuals with HIV-1 RNA <500 000 copies/mL.

SUBMITTER: Nyaku AN 

PROVIDER: S-EPMC6477973 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.

Nyaku Amesika N AN   Zheng Lu L   Gulick Roy M RM   Olefsky Maxine M   Berzins Baiba B   Wallis Carole L CL   Godfrey Catherine C   Sax Paul E PE   Acosta Edward P EP   Haas David W DW   Smith Kimberly Y KY   Sha Beverly E BE   Van Dam Cornelius N CN   Taiwo Babafemi O BO  

The Journal of antimicrobial chemotherapy 20190501 5


<h4>Background</h4>The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA 1000-500 000 copies/mL. Optimal ART for treatment-naive individuals must be durable.<h4>Objectives</h4>The aim of this study was to estimate the efficacy and safety of dolutegravir plus lamivudine at week 48 and compare the efficacy in participants with baseline HIV-1 RNA ≤100 000 copies  ...[more]

Similar Datasets

| S-EPMC5961075 | biostudies-literature
| S-EPMC5515053 | biostudies-literature
| S-EPMC5961309 | biostudies-literature
| S-EPMC7225620 | biostudies-literature
| S-EPMC6002106 | biostudies-literature
| S-EPMC10300912 | biostudies-literature
| S-EPMC6686958 | biostudies-literature
| S-EPMC4645960 | biostudies-literature
| S-EPMC3985528 | biostudies-literature
| S-EPMC8636802 | biostudies-literature